ClinicalTrials.gg
CompletedNCT05823948ONWARDS 9Updated Apr 30, 2026Results posted

A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)

A Phase 3 interventional study of Insulin Icodec in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 — 2 open to participants now, 2 under way, none of them phase 3. insulin icodec · Diabetes Mellitus, Type 2.

Enrollment
16th of 27
51 · median 84
Started
2023
with 2 others
Phase 3
9 of 27
none open now
Registered
23rd of 27
by date
Lead sponsor
26 of 27
Novo Nordisk A/S

Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, this one is the 16th largest by enrollment, is one of 3 that started in 2023, is one of 9 in phase 3, and was the 23rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About insulin icodec

insulin icodec: first FDA approval 2026 (AWIQLI FLEXTOUCH), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study looks at how a person with type 2 diabetes can be treated with insulin icodec and a flash glucose monitor (a small sensor inserted under the skin to measure blood sugar all the time). The study will look at how well insulin icodec controls blood sugar when used in combination with a flash glucose monitor. Participants will get insulin icodec that they have to inject once a week on the same day of the week. The insulin will be injected with a needle in a skin fold in the thigh, upper arm, or stomach. The study will last for about 8 months. Participants will have to wear a flash glucose monitor throughout the study. This is a sensor that fits on arm. Participants will be asked to use a commercially available app called LibreView to allow team to view flash glucose monitor data. Participants will get a study phone to scan the flash glucose monitor 4 times daily and they will be able to see all of the flash glucose monitor data during the study. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study
  • Age above or equal to 18 years at the time of signing informed consent
  • Diagnosed with type 2 diabetes (T2D) greater than or equal to (>=) 180 days before screening
  • from 7.0%-11.0% (53.0-96.7 millimoles per mole [mmol/mol]) both inclusive at screening confirmed by central laboratory analysis
  • Insulin-naïve. However, short term insulin treatment for a maximum of 14 consecutive days before screening is allowed, as is prior insulin treatment for gestational diabetes
  • Stable daily dose(s) >=90 days before screening of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator:

    1. Any metformin formulations >= 1500 milligrams (mg) or maximum tolerated or effective dose or
    2. Any metformin combination formulations >=1500 mg or maximum tolerated or effective dose or
    3. Other antidiabetic Drugs including combination products (>=half of the maximum approved dose according to local label or maximum tolerated or effective dose) of the classes specified below: Sulfonylureas, Meglitinides (glinides), Dipeptidyl peptidase-4 (DPP-4) inhibitors, Sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors, Thiazolidinedione, Alpha-glucosidase inhibitors, Oral combination products (for the allowed individual oral antidiabetic drugs, Oral or injectable glucagon-like peptide-1 (GLP-1) receptor agonists
  • Intensification with basal insulin is indicated to achieve fasting glycaemic target (4.4-7.2 millimoles per liter [mmol/L]; 80-130 milligrams per deciliter [mg/dL]) at the discretion of the treating investigator
  • (BMI) less than or equal to (\<=) 40.0 kilograms per meter square (kg/m\^2)

Exclusion criteria

Exclusion Criteria:

  • Unwilling or unable to avoid concomitant medication e.g., ascorbic acid (vitamin C) that can influence the flash glucose monitoring (FGM) sensor throughout the study and e.g., implanted medical devices such as pacemakers
  • Any episodes of diabetic ketoacidosis within 90 days before screening as declared by the participant or in the medical records
  • Myocardial infarction, stroke, or hospitalisation for unstable angina pectoris within 180 days before the day of screening and between screening and initiation visits
  • Chronic heart failure classified as being in (NYHA) Class IV at screening
  • Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g., treatment with orlistat, thyroid hormones, or )
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before the day of screening or in the period between screening and initiation visits. Pharmacological pupil dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Insulin Icodec

    Participants will receive 70 Units (U) insulin icodec subcutaneously once-weekly for 26 weeks.

    Drug: Insulin Icodec

Interventions

  • Participants will receive insulin icodec once-weekly subcutaneously into the thigh, upper arm or abdomen.

06

What researchers measure

Primary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c)

    Change in HbA1c from week 0 to week 26 is presented in percentage-point.

    Time frame: Baseline (week 0), week 26

07

Results

Posted Apr 30, 2026

Participant flow

The trial was conducted at 9 sites in United States of America.

Participant flow — Overall Study
MilestoneInsulin Icodec
Started51
Full analysis set51
Safety analysis set51
Completed50
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryChange in Glycosylated Haemoglobin (HbA1c)

Change in HbA1c from week 0 to week 26 is presented in percentage-point.

Time frame:
Baseline (week 0), week 26
Reported as:
Mean · Percentage-point of HbA1c
Change in Glycosylated Haemoglobin (HbA1c)
Percentage-point of HbA1cInsulin Icodec
Change in Glycosylated Haemoglobin (HbA1c)-1.18 ± 0.91

Adverse events

Collected over From week 0 up to week 31. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Icodec0/51 (0%)2/51 (3.9%)17/51 (33.3%)
Most frequent serious events
Most frequent serious events
EventInsulin Icodec
NephrolithiasisRenal and urinary disorders1/51
Snake biteInjury, poisoning and procedural complications1/51
Most frequent other events
Most frequent other events
EventInsulin Icodec
NasopharyngitisInfections and infestations7/51
COVID-19Infections and infestations5/51
Back painMusculoskeletal and connective tissue disorders4/51
HeadacheNervous system disorders3/51
Upper respiratory tract infectionInfections and infestations3/51

Baseline characteristics

Full analysis set (FAS) included all participants assigned to insulin icodec.

Age, Continuous
Age, Continuous(Years)Insulin Icodec
Mean61.27 ± 9.90
Sex: Female, Male
Sex: Female, Male(Participants)Insulin Icodec
Female21
Male30
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Insulin Icodec
Hispanic or Latino5
Not Hispanic or Latino46
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Insulin Icodec
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander1
Black or African American4
White44
More than one race0
Unknown or Not Reported0
08

Study locations

20 sites
  • Desert Oasis Hlthcr Med Group
    Palm Springs, California 92262, United States
  • Clinical Trials Research_Sacramento_0
    Sacramento, California 95821, United States
  • San Diego Family Care
    San Diego, California 92111, United States
  • Mills-Peninsula Hlth Services
    San Mateo, California 94401, United States
  • Florida Inst For Clin Res LLC
    Orlando, Florida 32825, United States
  • Metabolic Research Institute Inc
    West Palm Beach, Florida 33401, United States
  • East West Med Res Inst
    Honolulu, Hawaii 96814, United States
  • Northern Pines Hlth Ctr, PC
    Buckley, Michigan 49620, United States
  • International Diabetes Center
    Minneapolis, Minnesota 55416, United States
  • Palm Research Center Inc-Vegas
    Las Vegas, Nevada 89148, United States
  • Accellacare_NC
    Wilmington, North Carolina 28401, United States
  • Diabetes & Endocrinology Asso
    Canton, Ohio 44718, United States
  • AM Diabetes And Endocrinology
    Bartlett, Tennessee 38133, United States
  • Amarillo Medical Specialists
    Amarillo, Texas 79124, United States
  • Velocity Clin Res, Dallas
    Dallas, Texas 75230, United States
  • UT Southwestern Med Cntr
    Dallas, Texas 75390-9302, United States
  • Fmc Science, Llc
    Lampasas, Texas 76550, United States
  • Clinical Trials of Texas Inc
    San Antonio, Texas 78229, United States
  • Northeast Clinical Research of San Antonio
    San Antonio, Texas 78233, United States
  • Chrysalis Clinical Research
    St. George, Utah 84790, United States
09

References and documents

Publications

  • Bergenstal RM, Asbjornsdottir B, Johanning Bari T, Hulkund S, Winhofer Y, Wysham C. Continuous Glucose Monitoring-Based Titration of Once-Weekly Insulin Icodec in Insulin-Naive Individuals with Type 2 Diabetes (ONWARDS 9): A Phase 3b, Multicenter, Single-Arm, Treat-to-Target Clinical Trial. Diabetes Technol Ther. 2025 Jul;27(7):527-536. doi: 10.1089/dia.2025.0050. Epub 2025 Mar 5. PubMed 40040516 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Mar 2024, 10 months.

Results were first posted in Apr 2026, 2 years 1 month after primary completion. A results delay was requested in Mar 2025.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 10 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2023
First posted
Apr 21, 2023
StartActual
Apr 11, 2023
Primary completionActual
Mar 6, 2024
CompletionActual
Apr 11, 2024
Results delay requested
Mar 5, 2025
Results first posted
Apr 30, 2026
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05823948
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 21, 2023
Start date
Apr 11, 2023
Primary completion
Mar 6, 2024
Completion
Apr 11, 2024
Results posted
Apr 30, 2026
Last update
Apr 30, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin icodec

Start the discussion